Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04090034 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

Study acronym: PRRT
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 20, 2026 (before its estimated June 28, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Jun 28, 2024 to Jun 28, 2026v5
  2. Primary completion date: Jun 2026 to Jun 28, 2024v4 Show 4 more changesShow less
    • Start date: Jun 28, 2019 to Mar 28, 2024
    • Trial status: Enrolling by Invitation to Recruiting
    • Study sites: 1 to 2
    • Study completion date: Jun 2028 to Jun 28, 2024
  3. Study site revisedv3
  4. Study site revisedv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary NETs.
Trial Details
NCT Number NCT04090034
Lead Sponsor Methodist Health System
Conditions
(from sponsor)		 Neuroendocrine Tumors, Gastroenteropancreatic Neuroendocrine Tumor
Related terms Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov